ClinicalTrials.gg
CompletedNCT02024152Updated Mar 6, 2024

Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg

A Phase 1 interventional study of JDP-205 IV high dose and JDP-205 IV low dose in Acute Urticaria, sponsored by JDP Therapeutics, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-06.

Sponsored by JDP Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Urticaria with a site in Canada — 1 open to participants now, 2 under way, 1 of them phase 3. Urticaria · Canada.

Enrollment
12th of 13
24 · median 182
Started
2011
with 1 other
Phase 1
2 of 13
none open now
Registered
2nd of 13
by date
Lead sponsor
4 of 13
JDP Therapeutics, Inc.

Among the 13 studies in Urticaria with a site in Canada, this one is the 12th largest by enrollment, is one of 2 that started in 2011, is one of 2 in phase 1, and was the 2nd registered.

Urticaria

148 studies on the registry are indexed under Urticaria; 19 are open to participants now.

Browse Urticaria studies →

Open to participants now

1 of the 13 studies in Urticaria with a site in Canada is open now. Recruiting first, the newest first:

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 12 Urticaria studies recruiting now, 3 (25%) set no upper age limit and 6 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Urticaria with a site in Canada, or all of them as a file.
02

Study summary

This study is to investigate the pharmacokinetics (PK) together with the safety and tolerability of JDP-205 at 5 mg and 10 mg intravenous doses and 10 mg intramuscular dose, in comparison to the marketed cetirizine oral product Zyrtec® 10 mg tablets (an OTC product) in healthy male and female volunteers after a single dose administration.

03

Conditions studied

  • Acute Urticaria

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female volunteer
  2. Volunteer aged of at least 18 years
  3. Volunteer with a (BMI) greater than or equal to 18.50 and below 30.00 kg/m2
  4. Non- or ex-smokers; an ex-smoker being defined as someone who completely stopped smoking for at least 12 months before day 1 of this study.
  5. Availability for the entire study period
  6. Motivated volunteer and absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; ability to cooperate adequately; ability to understand and observe the instructions of the physician or designee
  7. Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance
  8. Have no diseases captured in the medical history or evidence of clinically significant findings on physical examination (including the examination of the anterolateral thigh muscles) and/or clinical laboratory evaluations (hematology, biochemistry, and urinalysis)
  9. Willingness to adhere to the protocol requirements as evidenced by the form (ICF) duly read, signed and dated by the volunteer

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant or are lactating
  2. Females of who refuse to use an acceptable regimen throughout the entire duration of the study (from the screening visit until study completion)
  3. History of significant to cetirizine or any related products (including of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
  4. Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
  5. History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability
  6. Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
  7. Suicidal tendency, history of or disposition to seizures, state of confusion, psychiatric diseases
  8. Presence of out-of-range cardiac interval (PR \< 110 msec, PR > 200 msec, QRS \< 60 msec, QRS >110 msec and > 440 msec) on the screening or other clinically significant ECG abnormalities
  9. Known presence of rare hereditary problems of galactose and /or lactose intolerance
  10. Maintenance therapy with any drug, or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
  11. Any clinically significant illness in the previous 28 days before day 1 of this study
  12. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, , phenytoin, rifampin and St John's Wort), in the previous 28 days before day 1 of this study
  13. Use of antihistaminic medication in the previous 7 days before day 1 of this study
  14. Any history of tuberculosis and/or prophylaxis for tuberculosis
  15. Positive urine screening of ethanol and/or drugs of abuse
  16. Positive results to HIV, or anti- tests
  17. Females who are pregnant according to a positive serum pregnancy test
  18. Volunteers who took an Product (in another clinical trial) or donated 50 mL or more of blood in the previous 28 days before day 1 of this study
  19. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    JDP-205 IV high dose

    Drug: JDP-205 IV high dose · Drug: JDP-205 IV low dose · Drug: JDP-205 IM

  • Experimental
    JDP-205 IV low dose

    Drug: JDP-205 IV high dose · Drug: JDP-205 IV low dose · Drug: JDP-205 IM

  • Experimental
    JDP-205 IM high dose

    Drug: JDP-205 IV high dose · Drug: JDP-205 IV low dose · Drug: JDP-205 IM

  • Active comparator
    Control

    Drug: Control: Zyrtec

Interventions

  • DrugJDP-205 IV high dose
  • DrugJDP-205 IV low dose
  • DrugJDP-205 IM
  • DrugControl: Zyrtec
06

What researchers measure

Primary outcomes

  1. Difference in pharmacokinetics: Difference in AUC

    Time frame: 36 hours post dose

  2. Differences in pharmacokinetics: difference in Cmax

    Time frame: 36 hours pose dose

07

Study locations

1 site
  • Algorithme Pharma
    Montreal, Quebec, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2013
First posted
Dec 31, 2013
Start
Mar 2011
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Last update
Mar 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02024152
Lead sponsor
JDP Therapeutics, Inc.
Collaborators
Algorithme Pharma Inc
Responsible party
Sponsor
First posted
Dec 31, 2013
Start date
Mar 2011
Primary completion
Jul 2011
Completion
Jul 2011
Last update
Mar 6, 2024
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion